The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.
The investment bank said that it thinks 2018 will be a good year for clinical sequencing and that overall demand for high-throughput sequencing remains high.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
In a report issued today, analysts said the company failed to provide "meaningfully improved visibility on broader reimbursement and revenue progression."
The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.
Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.
Vox explores a proposal to institute a lottery system to award grant funds.
In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.